BackPoniard Pharmaceuticals Overview

Poniard Pharmaceuticals Long Term Debt

Latest long-term debt for PARD: $1.6M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.64M
↓ 75.09% YoYΔ $-4.95M vs prior year quarter

Peer trimmed avg / median

Loading

Poniard Pharmaceuticals Long Term Debt History

Loading

Poniard Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Poniard Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Poniard Pharmaceuticals (PARD) FAQ

The latest long-term debt for PARD is $1.6M as of September 2011. That compares with $6.6M in the prior-year period — down 75.1% year over year. Investors often review this figure alongside Poniard Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PARD's long-term debt moved from $6.6M to $1.6M — a 75.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Poniard Pharmaceuticals's operating scale or balance-sheet position.

A long-term debt figure of $1.6M for PARD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting PARD's long-term debt ($1.6M), review year-over-year change from $6.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Poniard Pharmaceuticals's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.